LDH Levels May Mark Success of Elesclomol Plus Paclitaxel for Advanced Melanoma

This article originally appeared here.
Share this content:
Adding Elesclomol to Paclitaxel for Advanced Melanoma Studied
Adding Elesclomol to Paclitaxel for Advanced Melanoma Studied

(HealthDay News) -- Lactate dehydrogenase (LDH) levels may be predictive of success in treating chemotherapy-naive patients with advanced melanoma with a combination of elesclomol plus paclitaxel, according to research published online Feb. 11 in the Journal of Clinical Oncology.

Steven J. O'Day, M.D., of the Los Angeles Skin Cancer Institute in Beverly Hills, Calif., and colleagues conducted a randomized, double-blind trial of paclitaxel 80 mg/m² alone or with elesclomol 213 mg/m² as treatment for 651 chemotherapy-naive patients with advanced melanoma.

This study was ended prematurely due to a higher number of deaths in patients treated with paclitaxel alone; therefore, its primary progression-free survival (PFS) end point was not met. The researchers found that paclitaxel-only treated patients tended to have higher LDH levels. However, subgroup analysis did find that median PFS was significantly improved in patients who received combination treatment and who had normal baseline LDH levels.

"In conclusion, the SYMMETRY study did not achieve its primary end point," the authors write. "Prespecified and exploratory analyses suggest that baseline LDH levels may predict treatment outcomes for elesclomol. Literature reports suggest that LDH may more broadly predict activity of other anticancer agents specific for metabolic states of cancer cells."

The study was supported by Synta Pharmaceuticals, the manufacturer of elesclomol; several authors disclosed financial ties to pharmaceutical companies, including Synta.

Abstract
Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs